Search

Within the realms of human and artificial intelligence, the concepts of consciousness and comprehension are fundamental distinctions. In the clinical sphere, patient awareness regarding medication and its physiological processes plays a crucial role in determining drug efficacy and outcomes. This article introduces a novel perspective on prescription practices termed “Ultra-Overt Therapy” (UOT). A review of current supporting evidence was conducted through a non-systematic search in PubMed and Google Scholar, focusing on concepts such as the “mind–body relationship,” “placebo response,” “neuroscience,” and “complementary medicine.” Our findings, rooted in the mechanisms of the “placebo effect,” the intricacies of “intersubjective therapy,” the potency of “interoceptive awareness,” and other domains of medical science, suggest that UOT holds theoretical promise. Future research endeavors focusing on these areas may elucidate the global impact of this method on medical treatment and patient care. [ABSTRACT FROM AUTHOR]

Introduction: Pieces of evidence indicate a relationship between breast cancer and type 2 diabetes (T2D) which is a potential risk factor for breast cancer development and progression. Hyperinsulinemia, insulin resistance, chronic inflammation, inflammatory cytokines, and hormonal factors are possible explanations for this association. T2D may also affect the breast cancer treatment course. Neoplastic cells are more chemo-resistant, and chemotherapy adverse effects are more prominent in patients with diabetes and breast cancer at the same time. Diabetic nephropathy is one of the T2D complications that should be considered prior to choosing a therapeutic protocol for breast cancer patients. Hence, collaboration between oncologists, endocrinologists, and nephrologists is essential to provide comprehensive care for T2D and breast cancer patients. [ABSTRACT FROM AUTHOR]

Histopathologic lesions associated with rapamycin-associated nephropathy (RAN) include collapsing focal segmental glomerulosclerosis, delayed graft function with cast nephropathy, and acute renal injury with increased intratubular cast formation. [ABSTRACT FROM AUTHOR]

This article, titled "Cancer in systemic lupus erythematosus; a letter to the editor on current concepts," discusses the association between systemic lupus erythematosus (SLE) and cancer. The authors highlight that individuals with SLE are prone to developing various malignancies, although the exact relationship is not well understood. They cite several studies and meta-analyses that demonstrate an increased risk of overall cancer, digestive cancers, hematologic malignancies, and pulmonary cancers in SLE patients. The authors suggest that physicians should be aware of this association and regularly monitor SLE patients for cancer. [Extracted from the article]